000			04249nam a22004095i 4500
001			75872
003			ES-MaUEC
005			20230207040201.0
007			cr nn 008mamaa
008			121009s2013 xxu| s |||| 0|eng d
020			_a9781461446699
024	7		_a10.1007/978-1-4614-4669-9 _2doi
040			_aES-MaUEC
050		4	_aQP801.C27 _bE53 2013
082	0	4	_a612.8
245	0	0	_aEndocannabinoids : _bactions at Non-CB1/CB2 cannabinoid receptors _cedited by Mary E. Abood, Roger G Sorensen, Nephi Stella
260			_aNew York _bSpringer International Publishing _c2013
300			_a1 recurso en línea (XI, 286 p.) _b41 ilustraciones, 21 ilustraciones en color
336			_aTexto (visual) _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
490	0		_aThe Receptors _v24
505	0		_aOverview of Non-Cannabinoid Receptors.Overview of Non-Classical Cannabinoid Receptors.Overview of Non-Cannabinoid Receptors: Chemistry and Modeling -- G-Protein Coupled Receptors.GPR55 in the CNS.The Role of GPR55 in Bone Biology.The Role of GPR55 in Cancer.GPR18 and NAGly signaling: New members of the endocannabinoid family or distant cousins?.Cannabinoid Signaling Through Non CB1/Non CB2 GPCR Targets in Microglia -- Ion Channels.Temperature-Sensitive Transient Receptor Potential Channels as Ionotropic Cannabinoid Receptors.Nonpsychoactive Cannabinoid Action on 5-HT3 and Glycine Receptors -- Transcription Factors.Peroxisome proliferator-activated receptors and inflammation.Peroxisome proliferator-activated nuclear receptors (PPAR) and drug addiction -- Conclusions/Therapeutic Potential.Conclusions: Therapeutic Potential of Novel Cannabinoid Receptors
520			_aThe cloning of two G protein-coupled cannabinoid receptors, termed CB1 and CB2, in the early 1990s has stimulated and facilitated research conducted on the physiological function of cannabinoid actions in the brain and throughout the body. In the twenty years since the identification of these two receptors, endogenous ligands (endocannabinoids) for these receptors have been identified, their biosynthetic and metabolic pathways have been discerned, and their functional and regulatory action for signalling through CB1 and CB2 receptors have been described. More recently, it has become has become evident that cannabinoids exert actions at non-CB1, non-CB2 receptors. Much less is understood about these actions. Many of these novel g2stargetsg3s are in the process of being characterized functionally and physiologically, and the therapeutic value of targeting these non-CB1, non-CB2 receptors is being evaluated. The purpose of this volume is to present the current knowledge on the atypical actions of cannabinoids on these new targets. This book is intended as a scientific resource for cannabinoid researchers carrying out animal and human experiments, and for those who are interested in learning about future directions in cannabinoid research. Additionally, this book may be of value to investigators currently working outside the field of cannabinoid research who have an interest in learning about these compounds and their atypical cannabinoid signalling. This book provides insight into the potential medical application of cannabinoids and their therapeutic development for the treatment of human disease
942			_2lcc _cLE
988			_aEBOOK, EBSPRINGERrevisado
650		7	_aMarihuana _xEfectos fisiológicos _9253876 _0comprobar BNE19980839549 _2embne
650		7	_aFarmacología _0comprobar BNE19900953030 _2embne _9137893
700	1		_aAbood, Mary E. _eeditor literario _984567 _0Local
700	1		_aSorensen, Roger G. _eeditor literario _984568 _0Local
700	1		_aStella, Nephi _eeditor literario _984569 _0Local
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://link.springer.com/book/10.1007/978-1-4614-4669-9 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
901			_ai9781461446699
907			_a.b12814908 _b10-10-17 _c01-10-14
998			_am _a_alco _a_vill _b29-03-17 _cm _dz _eb _feng _gxxu _h0
945			_aQP801.C27 E53 2013 EB _g1 _ieBOOK _j0 _lmae _o- _pEUR0.00 _q- _r- _sb _t15 _u0 _v0 _w0 _x0 _y.i11544284 _z06-04-17
999			_c75872 _d75872 _x1